Novel approaches to selective treatments of human solid tumors: laboratory and clinical correlation / edited by Youcef M. Rustum. p. cm. -- (Advances in experimental medicine and biology ; v. 339)
  Includes bibliographical references and index.
  ISBN 0-306-44592-1
  RC271.F55N88 1993
  618.99 4081--dc20
  DNL/M/DLC
  for Library of Congress

Proceedings of an international symposium on Novel Approaches to Selective Treatments of Human Tumors: Laboratory and Clinical Correlation, held September 10–12, 1992, in Buffalo, New York

ISBN 0-306-44592-1

A Division of Plenum Publishing Corporation
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America
CONTENTS

Fluoropyrimidine Metabolism and Mechanism of Action

5-Fluoro-2'-Deoxyuridine: Role of Schedule in its Therapeutic Efficacy
S. Cao, Z-G Zhang, P.J. Creaven and Y.M. Rustum

Comparison of Continuous Infusions and Bolus Injections of 5-Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase
G.J. Peters, G. Codacci-Pisanelli, C.L. van der Wilt, J.A.M. van Laar, K. Smid, P. Noordhuis, H.M. Pinedo

Discussion

Critical Questions for the Future Direction of FU/LV

Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate
J. Jolivet and R. Bertrand

Leucovorin as a Prodrug
D. G. Priest, J.C. Schmitz and T. Walle

Discussion

Clinical Use of Leucovorin: Intracellular Metabolism
C.J. Allegra and Donna Voeller

Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089)
D.G. Haller, M. Lefkopoulou, J.S. Macdonald and R.S. Mayer

Discussion

Effects of 5-Fluorouracil on mRNA
B.J. Dolnick and X-P. Wu
Discussion

Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine

Experience with 5FU + L-Leucovorin

5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of Two Consecutive Regimens

Discussion

5-Fluorouracil Modulation in Colorectal Carcinoma: Experience of German Investigators
C.H. Kohne-Wompner, H.J. Schmoll

An Overview of Adjuvant Treatment of Colon Cancer
S. Fine

Discussion

Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-(Phosphonacetyl)-L-Aspartate
J.L. Grem, N. McAtee, J.C. Drake, S. Steinberg and C.J. Allegra

Alternative Approaches to Modulation of Fluoropyrimidines

Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies
J.A. Sparano and S. Wadler

Enhanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and Recombinant Human Interferon-α2a in Colon Carcinoma Cells
J.A. Houghton, D.A. Adkins and P.J. Houghton

Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma
E. Chu and C.J. Allegra
Biochemical Modulation of 5-Fluorouracil by PALA: Mechanism of Action

D. S. Martin

Discussion

153

Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy


169

General Discussion

185

Update on Metabolic Modulation as a Therapeutic Approach for Adult Carcinomas

Fluorouracil and Leucovorin in Advanced Breast Cancer


187

Discussion

195

Fluorouracil Modulation in Head and Neck Cancer

E.E. Vokes

197

Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe

J. Eskandari

209

Discussion

219

Rationale for the Combination Therapy of 5FU and CDDP

N. Saijo and Y. Sugirnoto

223

Biochemical Modulation of Fluoropyrimidines: The "Giscad" Studies


233

General Discussion

239

New Drugs

Clinical Experience with UFT in Japan

M. Kurihara

243

Clinical Studies of the Modulation of Florafor

P.J. Creaven, Y.M. Rustum, N.J. Petrelli and V. A. Gorbunova

253

Discussion

263
The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694
A.L. Jackman, W. Gibson, M. Brown, R. Kimbell and F. Thomas Boyle

The History of the Development and Clinical Use of CB 3717 and ICI D1694
S.J. Clarke, A.L. Jackman and I.R. Judson

Discussion

NEW SITES OF INTERVENTION IN THE DEVELOPMENT OF NEW DRUGS IN SOLID TUMORS

P53: A Determinant of the Cell Cycle Response to DNA Damage
M.B. Kastan

Discussion

Therapeutic Implications of Molecular Genetics
S.R. Hamilton

Discussion

Concluding Remarks

Summary
E. Mihich

Abbreviations

Author Index

Subject Index